Literature DB >> 10378427

Impact of ELISA and immunoblot as diagnostic tools one year after eradication of Helicobacter pylori in a multicentre treatment study.

M Kist1, S Strobel, T Kirchner, H G Dammann.   

Abstract

The performance of serological tests for Helicobacter pylori infections is hampered by the persistence of antibodies after eradication therapy or spontaneous healing. Detection of different antigens or immunoglobulin classes might have an impact on the validity of serodiagnosis. The aim of this study was to assess the decrease in IgA and IgG antibody levels after eradication of H. pylori. Serum samples of 242 patients with active duodenal ulcer were tested with the ELISA and the immunoblot (IB) techniques for H. pylori-specific IgA and IgG antibodies before therapy and 1 year after successful eradication. From a total of 81 patients paired sera were available. At the end of the follow-up period ELISA antibody titres from the IgA class had decreased from a mean value of 6.69 to 4.26 units (P = 0.0001), and IgG class antibody titres from a mean value of 21.9 to 12.1 units (P = 0.0001). Regarding seroreversion, from 34 initially IgA positive sera 16 (47%), and from 74 IgG positive sera 18 (24%), had definitively reverted to 'negative'. One year after eradication, when tested with the immunoblot, the antibody responses against specific antigens of 37% IgA-positive sera (23/62) and 8% IgG-positive sera (6/78) reverted to 'negative', compared to a seroreversion rate of 27% of the anti-CagA IgA-positive sera (18/67) and of 9% of the anti-CagA IgG-positive sera (7/79). In conclusion, despite an overall significant decrease of H. pylori antibodies, both tests cannot be recommended for monitoring treatment success.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10378427     DOI: 10.1111/j.1574-695X.1999.tb01289.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  8 in total

1.  Evaluation of the role of H pylori infection in pathogenesis of gastric cancer by immunoblot assay.

Authors:  Kuo-Ching Yang; Alexander Chu; Chao-Sheng Liao; Yu-Min Lin; Gen-Min Wang
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

2.  ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer: a case-control study.

Authors:  Harvey A Risch; Herbert Yu; Lingeng Lu; Mark S Kidd
Journal:  J Natl Cancer Inst       Date:  2010-02-24       Impact factor: 13.506

3.  Immunoglobulin G antibody response to infection with coccoid forms of Helicobacter pylori.

Authors:  G Figueroa; G Faúndez; M Troncoso; P Navarrete; M S Toledo
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

4.  Evaluation of a commercial immunoblot, Helicoblot 2.1, for diagnosis of Helicobacter pylori infection.

Authors:  Lea Veijola; Aino Oksanen; Pentti Sipponen; Hilpi Rautelin
Journal:  Clin Vaccine Immunol       Date:  2008-09-30

5.  Association between Helicobacter pylori infection and pancreatic cancer development: a meta-analysis.

Authors:  Mingjia Xiao; Yiming Wang; Yi Gao
Journal:  PLoS One       Date:  2013-09-26       Impact factor: 3.240

Review 6.  Diagnosis of Helicobacter pylori: Changes towards the Future.

Authors:  Behnam Kalali; Luca Formichella; Markus Gerhard
Journal:  Diseases       Date:  2015-06-29

7.  Validation of a Novel Immunoline Assay for Patient Stratification according to Virulence of the Infecting Helicobacter pylori Strain and Eradication Status.

Authors:  Luca Formichella; Laura Romberg; Hannelore Meyer; Christian Bolz; Michael Vieth; Michael Geppert; Gereon Göttner; Christina Nölting; Wolfgang Schepp; Arne Schneider; Kurt Ulm; Petra Wolf; Ingrid Lisanne Holster; Ernst J Kuipers; Bernd Birkner; Erwin Soutschek; Markus Gerhard
Journal:  J Immunol Res       Date:  2017-05-30       Impact factor: 4.818

Review 8.  Non-invasive diagnostic tests for Helicobacter pylori infection.

Authors:  Lawrence Mj Best; Yemisi Takwoingi; Sulman Siddique; Abiram Selladurai; Akash Gandhi; Benjamin Low; Mohammad Yaghoobi; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2018-03-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.